Last updated: May 5, 2026
Ultravist 300 (iopromide): Clinical Trials Update, Market Analysis, and 2025-2035 Projection
What is Ultravist 300 and what indications does it cover?
Ultravist 300 is a contrast medium containing iopromide 300 mg I/mL (300 mg iodine per mL). It is used in diagnostic imaging across major radiology modalities, principally computed tomography (CT) and other radiologic procedures where iodinated contrast is indicated.
Key positioning for market reads: Ultravist 300 is an off-patent, branded iodinated contrast product in a mature segment where competition is driven by formulary access, tender pricing, and supply reliability rather than by patent-protected innovation.
What do recent clinical-trial signals show for iopromide (Ultravist 300)?
No drug-development clinical trial “pipeline” update is attributable to Ultravist 300 as a distinct proprietary program in the way it would be for a patent-protected small molecule or biologic. In practice, the clinical literature landscape for iodinated contrast is dominated by:
- Use-pattern studies (dose optimization, safety outcomes, imaging protocols)
- Comparative effectiveness against other iodinated contrast agents
- Special populations studies (kidney function, pediatrics, allergy risk mitigation)
- Imaging workflow research (CT angiography protocols, timing, bolus strategies)
Because Ultravist 300 is iopromide, the operational “clinical trials update” for decision-making is best read at the substance class level (iopromide) and at the comparative safety and protocol level, not at a branded late-stage pipeline level.
Evidence base typically used for ongoing clinical assurance in iopromide
Across CT practice, iodinated contrast dosing and safety are repeatedly studied, including:
- Risk of contrast-associated acute kidney injury (CA-AKI) and prevention strategies in at-risk cohorts.
- Allergic-like hypersensitivity incidence and premedication approaches.
- Image quality and artifact profiles (workflow and dose).
The dominant implication for Ultravist 300 commercialization: clinical activity continues, but it supports label usage and protocol optimization, not a new competitive differentiation that would shift long-duration market share absent procurement dynamics.
Is Ultravist 300 linked to any active, label-changing late-stage trials?
No label-changing late-stage development program tied to Ultravist 300 has a clear, product-specific clinical-trial signature in publicly indexed registries in a way that would support an R&D-stage update or a new patent-cycle claim for the branded product.
For business planning, this means:
- Market outlook depends primarily on tendering and hospital formularies
- Any “trial impact” is likely incremental protocol confidence rather than a step-change in adoption
- Differentiation typically arises from supply chain performance, packaging, and procurement price rather than breakthrough trial outcomes
What is the market structure for iodinated CT contrast (where Ultravist 300 competes)?
Ultravist 300 competes in the iodinated contrast media market, a mature category with established supply chains and large incumbents. The competitive map is shaped by:
- Portfolio breadth (multiple iodine concentrations and viscosity profiles)
- Hospital contracting (regional tenders)
- Clinical preference (radiology department protocols)
- Availability and logistics (critical for imaging throughput)
Competitive set (portfolio-level)
In practice, competitive comparisons are made against other iodinated contrast media brands and molecules used for CT and angiography, including (among others) iohexol, ioversol, iodixanol, and others. Switching within the class is common when procurement terms change.
Key market drivers
The category demand driver is the volume of CT and other radiology procedures, which is influenced by:
- Aging demographics
- Cancer screening and staging
- Cardiovascular imaging growth
- Emergency and trauma imaging intensity
- Health system capacity and throughput
The key market constraint is cost and procurement leverage. Because these are off-patent products or in mature lifecycles, price pressure and tender dynamics often matter more than marketing.
What does the pricing and adoption dynamic imply for Ultravist 300?
Ultravist 300 faces:
- Erosion of branded premium versus competitors with equivalent clinical performance
- Purchasing consolidation that favors large-scope contracts
- Regional variation in formulary placement
For projection modeling, the practical assumption is that Ultravist 300’s growth will track imaging demand but show limited market share expansion unless procurement contracts or supply issues shift.
Market projection: 2025-2035 outlook for Ultravist 300
Because Ultravist 300 is iopromide in a mature iodinated contrast market, the projection must be driven by:
- Imaging volume growth (CT demand)
- Unit consumption (dose distribution depends on protocols)
- Price trend (contract-based and tender-driven)
- Share stability (brand-level substitution within class)
Projection framework (base-case)
- Demand growth: tracks imaging utilization growth in developed markets and continues expanding in emerging regions
- Price: moderate decline or flat-to-down in many regions due to tender pressure and class interchangeability
- Volume vs value: volume may rise faster than revenue due to pricing compression
10-year scenario outcomes (value and unit directionality)
- Base case (most likely):
- Units: grow with CT procedural demand
- Revenue: grows slower than units due to procurement price pressure
- Upside:
- Faster share capture via procurement wins, improved supply reliability, and switching catalysts
- Downside:
- More aggressive tender pricing and replacement by alternative agents with favorable contracting terms
Practical business projection (actionable KPIs)
For a hospital-systems investor or commercial planner, the measurable outcomes typically translate to:
- Share of CT contract lines
- Tender win rate and average contract price per mL
- Seasonality and supply stability metrics
- Formulary retention across major hospital networks
This is where Ultravist 300’s performance will show up, more than in pipeline milestones.
What should investors and R&D leaders track for Ultravist 300 over the next 12-24 months?
- Tender outcomes by region (price concessions vs stability)
- Contracting shifts among large radiology networks
- Supply and manufacturing continuity (contrast media shortages can cause temporary displacement)
- Protocol changes in CT departments (dose usage and imaging workflow)
- Regulatory actions affecting iodinated contrast labeling (warnings, renal safety language updates)
Key constraints unique to iodinated contrast commercialization
- Clinical interchangeability within iodinated classes limits sustainable premium.
- Procurement cycles dominate commercial cadence.
- Regulatory updates are incremental but can re-tier products in formulary ranking.
- Procurement consolidation can lock in share for years, making contract acquisition decisive.
Key Takeaways
- Ultravist 300 is iopromide (300 mg I/mL), a mature CT contrast product where market performance is mainly procurement- and supply-driven rather than pipeline-driven.
- Clinical-trial activity is present at the protocol and safety-evidence level, but no distinct late-stage, label-changing Ultravist 300 development program is the basis for a material competitive shift.
- Projection for 2025-2035 should model volume growth with CT utilization and value growth constrained by tender-driven pricing compression, with share broadly stable absent procurement wins or supply displacement.
FAQs
1) Does Ultravist 300 have an active late-stage pipeline that could change its market position?
No product-specific late-stage, label-changing development program is identifiable as a distinct driver for Ultravist 300 market position.
2) What determines Ultravist 300 revenue more: procedure volumes or price?
Revenue is typically more sensitive to contract price because these products are class-interchangeable within iodinated contrast media.
3) Can hospitals switch from Ultravist 300 to other contrast agents easily?
Yes. Within iodinated contrast classes, switching is common and driven by tender terms and formulary protocols.
4) What clinical data is most likely to influence adoption of iopromide-based products?
Protocol and safety evidence focused on renal risk management and hypersensitivity risk, plus image-quality outcomes tied to CT protocols.
5) What is the most actionable monitoring approach for commercial planning?
Track regional tender outcomes, contract win rate, average mL pricing, and formulary retention across major hospital networks.
References
[1] ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. American College of Radiology.
[2] European Medicines Agency (EMA). Product information and assessment documents for iopromide/Ultravist (where applicable). EMA.
[3] FDA. Drug Safety and Contrast Media Guidance documents and labeling frameworks (where applicable). U.S. Food and Drug Administration.
[4] PubMed. Clinical studies on iodinated contrast media safety, CA-AKI, and hypersensitivity (includes iopromide comparative and protocol studies). National Library of Medicine.
